The tremendous impact of CRISPR as a genome-editing tool on the research community has created hope and opportunity for the development of truly durable therapies. Several such approaches will soon yield clinical data suggesting 2020 and 2021 will be important years for understanding how (and if) these therapies will achieve early success. While many key issues have been addressed, many challenges (and coincident opportunities) still exist. These will be discussed on the backdrop of developing in vivo and ex vivo therapies in an industrial setting.
Advancing Genome Editing Therapeutics:
Challenges and Opportunities
Dr. Vic Myer
We strive to make our events accessible and inclusive. The Innovative Genomics Institute Building is ADA accessible, and has a lactation room that visitors can use. For disability accommodation information and requests and/or access to the lactation room, please contact Kristy Nordahl at firstname.lastname@example.org or 510-664-7110.